Literature DB >> 6853832

Monitoring aminophylline therapy using Jusko's dosage guidelines.

E P Calandre, A J Perez de la Cruz, A M Morales, N P Alférez, E Moreno, G V Mata.   

Abstract

Treatment with aminophylline, according to the nomogram published by Jusko and coworkers, was monitored in 13 patients suffering from acute exacerbations of COPD. After 24 h of therapy, the clinical state, the pO2 and the pCO2 values were markedly improved. Theophylline plasma concentrations were maintained within the therapeutic range. A slight but noticeable increase of drug serum levels during therapy could be related to changes in the arterial pH; the implications of this finding are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6853832     DOI: 10.1007/bf01699261

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  6 in total

1.  Effect of pH on the binding of theophylline to serum proteins.

Authors:  J J Vallner; W A Speir; R C Kolbeck; G N Harrison; E D Bransome
Journal:  Am Rev Respir Dis       Date:  1979-07

2.  Rational intravenous doses of theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  N Engl J Med       Date:  1973-09-20       Impact factor: 91.245

3.  Intravenous theophylline therapy: nomogram guidelines.

Authors:  W J Jusko; J R Koup; J W Vance; J J Schentag; P Kuritzky
Journal:  Ann Intern Med       Date:  1977-04       Impact factor: 25.391

4.  Kinetics of theophylline; variability and effect of arterial pH in chronic obstructive lung disease.

Authors:  R K Resar; P D Walson; W L Fritz; D F Perry; R A Barbee
Journal:  Chest       Date:  1979-07       Impact factor: 9.410

5.  Theophylline protein binding in humans.

Authors:  K J Simons; F E Simons; C J Briggs; L Lo
Journal:  J Pharm Sci       Date:  1979-02       Impact factor: 3.534

6.  Theophylline serum protein binding in obstructive airways disease.

Authors:  L J Lesko; K J Tabor; B F Johnson
Journal:  Clin Pharmacol Ther       Date:  1981-06       Impact factor: 6.875

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.